Exploring CACNA1H as a potential candidate biomarker for calcific aortic valve disease

  • iScience. 2026 Apr 27;29(5):115616. doi: 10.1016/j.isci.2026.115616.
Jun Chen  1  2 Liusheng Wang  1  2 Wenyan Li  1  2 Shunyi Li  1  2 Xiaolin Duan  1  2 Sijie Jiang  1  2 Zhen Zhang  3 Qingchun Zeng  1  2
Affiliations
  • 1. State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  • 2. Guangdong Provincial Key Laboratory of Shock and Microcirculation, Southern Medical University, Guangzhou 510515, China.
  • 3. Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Abstract

Calcific aortic valve disease (CAVD) is a prevalent cardiovascular disorder characterized by calcium deposition in the aortic valve, associated with high morbidity and mortality. Mechanical stress plays a key role in its pathogenesis, highlighting the importance of identifying mechanosensitive ion channel-related genes (MICRGs). In this study, transcriptome data from GSE83453 of patients with CAVD and healthy controls were analyzed to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) and MICRGs were used to pinpoint key genes. The intersection of DEGs, WGCNA modules, and MICRGs identified CACNA1H as a candidate gene. External validation with GSE51472 and GSE55492 confirmed these findings. Both in vitro and in vivo studies confirmed that CACNA1H inhibition alleviates CAVD progression by repressing the osteogenic response. Mechanistically, CACNA1H inhibition attenuated phosphorylation of P65, a key regulator of the NF-κB pathway. These results suggest that CACNA1H may serve as a promising biomarker and therapeutic target for CAVD.

Keywords
Cardiovascular medicine; Health sciences; Internal medicine; Medical specialty; Medicine.
Products